Custom Synthesis drives earnings

Company

27 May 2024 | 5 Min Read

Divis Laboratories' financial performance and valuation changes are highlighted.

The company's revenue and EBITDA margins improved in 4QFY24.

The company's focus on Custom Synthesis and API segments is driving growth.

The management expects a 27% earnings CAGR over FY24-26.

The company's valuations capture the earnings upside, leading to a neutral rating.

Divis Laboratories is making strides in both the CS and API segments.